Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 58,424 Shares

Key Points

• Insider sale: CEO/insider John Paolini sold 58,424 shares on May 1 at an average of $53.71 for about $3.14 million under a pre‑arranged Rule 10b5‑1 plan, reducing his position by 47.1% to 65,623 shares.
• Strong quarter: Kiniksa beat expectations with $0.27 EPS vs. $0.18 estimate and revenue of $214.3M (up 55.5% year-over-year), with analysts forecasting $1.22 EPS for the year.
• Positive analyst outlook: Multiple firms raised price targets (Jefferies to $71, Wells Fargo to $57, Citi to $60) and the stock carries an average "Moderate Buy" rating with a mean target of about $60.86.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) insider John Paolini sold 58,424 shares of the company's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the sale, the insider owned 65,623 shares in the company, valued at $3,524,611.33. The trade was a 47.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA traded down $0.88 during trading hours on Tuesday, hitting $56.74. 624,640 shares of the company traded hands, compared to its average volume of 710,959. The business's 50-day moving average is $46.40 and its 200-day moving average is $43.20. The stock has a market capitalization of $4.34 billion, a price-to-earnings ratio of 63.04 and a beta of 0.17. Kiniksa Pharmaceuticals International, plc has a twelve month low of $24.85 and a twelve month high of $58.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.11 EPS. Analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.22 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its position in Kiniksa Pharmaceuticals International by 20.2% in the first quarter. Bank of New York Mellon Corp now owns 17,388 shares of the company's stock valued at $837,000 after purchasing an additional 2,917 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at approximately $248,000. Inspire Investing LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at approximately $1,698,000. Cannon Global Investment Management LLC acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $530,000. Finally, SG Americas Securities LLC grew its holdings in Kiniksa Pharmaceuticals International by 18.2% during the 1st quarter. SG Americas Securities LLC now owns 640,179 shares of the company's stock worth $30,825,000 after acquiring an additional 98,783 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an "overweight" rating in a research note on Wednesday, April 29th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "hold" rating to a "strong-buy" rating in a report on Monday. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a research report on Friday, April 17th. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a "buy" rating in a research report on Tuesday, April 28th. Finally, Citigroup lifted their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a "buy" rating in a research note on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of "Moderate Buy" and an average price target of $60.86.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.